Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Its lead product candidate is the ADG20, a neutralizing antibody that is in Phase II/III clinical trials for the treatment and prevention of coronavirus disease. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. Adagio Therapeutics, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: adagiotx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2022 | $11.00 → $6.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/6/2022 | Overweight → Underweight | Morgan Stanley | |
| 12/22/2021 | $46.00 → $10.00 | Buy → Hold | Jefferies |
| 12/15/2021 | $49.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
| 12/15/2021 | Buy → Neutral | Guggenheim | |
| 12/15/2021 | $50.00 → $9.00 | Buy → Hold | Stifel |
| 11/29/2021 | $49.00 | Equal-Weight → Overweight | Morgan Stanley |
| 8/31/2021 | $33.00 | Equal-Weight | Morgan Stanley |
| 8/31/2021 | $60.00 | Buy | Jefferies |
| 8/31/2021 | $57.00 | Buy | Stifel |
Novel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023 $419 million in cash, cash equivalents and marketable securities expected to support operating runway into Q2 2024 Conference call scheduled for Thursday, November 10th at 4:30 p.m. ET WALTHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced financial results and business highlights for the third quarter ended September 30, 2022. "It has been a productive quarter starting with a corporate rebrand emphasizing our commitment to e
WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced that it will host a conference call on Thursday, November 10, 2022, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2022, and recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan o
WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David Hering, chief executive officer of Invivyd, is scheduled to present at Cowen's 43rd Annual Healthcare Conference on Monday, March 6, 2023 at 2:10 p.m. ET. A live webcast of the presentation will be available in the investor section of the company's website at investors.invivyd.com and will be archived for 90 days following the presentation. About Invivyd(NASDAQ:IVVD)Invivyd, Inc., formerly Adagio Therapeutics (NASDAQ:ADGI), is a biopharmaceutical company on a mission to prot
WALTHAM, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical stage biopharmaceutical company on a mission to protect humanity from serious infectious diseases, today announced that Laura Walker, Ph.D., the company's chief scientific officer and co-founder, decided to leave the company to pursue other opportunities. The management team has initiated a search process to identify her replacement. Until a permanent successor is named, Invivyd team member Lukas Dillinger, Ph.D., has been appointed as interim Head of Discovery and Pre-Clinical. "On behalf of the company, I extend my gratitude and thanks for Laura's scientific passion and contributions that led to
WALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, was invited to participate in an FDA-EMA workshop on SARS-CoV-2 monoclonal antibodies held on December 15, 2022. Invivyd's chief scientific officer, Laura Walker, Ph.D., alongside Eli Lilly and Company and Regeneron Pharmaceuticals, Inc., presented a joint industry approach for anti-spike monoclonal antibody development to keep pace with SARS-CoV-2 variants. The meeting featured presentations by scientists, clinicians, regulators, and industry representatives to discuss alternative strategies to s
WALTHAM, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Jeremy Gowler as chief operating and commercial officer, effective December 16, 2022, and the promotion of Pete Schmidt, M.D. to chief medical officer, effective immediately. In his new role Mr. Gowler will oversee operations and commercial activities for the company. Dr. Schmidt will be responsible for overseeing all medical, clinical development and regulatory activities at Invivyd. Dr. Ellie Hershberger, Invivyd's chief development officer, is departing f
-Broad partnership will strengthen Invivyd's development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies for COVID-19 and beyond- -Population Health Partners to integrate best-in-class capabilities to drive speed and efficiency in clinical development, demonstrated by the success of PHP's leadership team at The Medicines Company, Pfizer and elsewhere in the life sciences industry- WALTHAM, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced a partnership with Populat
Novel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023 $419 million in cash, cash equivalents and marketable securities expected to support operating runway into Q2 2024 Conference call scheduled for Thursday, November 10th at 4:30 p.m. ET WALTHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced financial results and business highlights for the third quarter ended September 30, 2022. "It has been a productive quarter starting with a corporate rebrand emphasizing our commitment to e
WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David Hering, chief executive officer of Invivyd, is scheduled to participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 4:25 p.m. GMT. A live webcast of the fireside chat will be available in the investor section of the company's website at investors.invivyd.com and will be archived for 90 days following the presentation. About Invivyd(NASDAQ:IVVD)Invivyd, formerly Adagio Therapeutics (NASDAQ:ADGI), is a biopharmaceutical com
WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced that it will host a conference call on Thursday, November 10, 2022, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2022, and recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan o
WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Christine Lindenboom, senior vice president investor relations & corporate communications at Alnylam Pharmaceuticals, Inc., to its board of directors. In addition, Redonda Miller, M.D., M.B.A., president of The Johns Hopkins Hospital, has stepped down from her position on the board. "We are excited to welcome Christine to our board of directors where her business acumen and deep knowledge of the biopharmaceutical industry will round out and enhance our current b
WALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Invivyd, (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Fred Driscoll as interim CFO as well as headcount changes to align resources to its key programs. The changes are designed to improve capital efficiency by reallocating resources to programs and functions to support our key activities on an accelerated timeline. As part of the resource realignment, the company is building out additional discovery and early development positions and has eliminated several corporate and commercial positions, among others, to execute effi
8-K - Invivyd, Inc. (0001832038) (Filer)
8-K - Invivyd, Inc. (0001832038) (Filer)
D - Invivyd, Inc. (0001832038) (Filer)
8-K - Invivyd, Inc. (0001832038) (Filer)
10-Q - Invivyd, Inc. (0001832038) (Filer)
8-K - Invivyd, Inc. (0001832038) (Filer)
8-K - Invivyd, Inc. (0001832038) (Filer)
8-K - Invivyd, Inc. (0001832038) (Filer)
EFFECT - Invivyd, Inc. (0001832038) (Filer)
S-3 - Invivyd, Inc. (0001832038) (Filer)
4 - Invivyd, Inc. (0001832038) (Issuer)
4 - Invivyd, Inc. (0001832038) (Issuer)
4 - Invivyd, Inc. (0001832038) (Issuer)
4 - Invivyd, Inc. (0001832038) (Issuer)
3 - Invivyd, Inc. (0001832038) (Issuer)
4 - Invivyd, Inc. (0001832038) (Issuer)
4 - Invivyd, Inc. (0001832038) (Issuer)
3 - Invivyd, Inc. (0001832038) (Issuer)
4 - Invivyd, Inc. (0001832038) (Issuer)
4 - Invivyd, Inc. (0001832038) (Issuer)
Morgan Stanley downgraded Adagio Therapeutics from Equal-Weight to Underweight and set a new price target of $6.00 from $11.00 previously
Morgan Stanley downgraded Adagio Therapeutics from Overweight to Underweight
Jefferies downgraded Adagio Therapeutics from Buy to Hold and set a new price target of $10.00 from $46.00 previously
Morgan Stanley downgraded Adagio Therapeutics from Overweight to Equal-Weight and set a new price target of $11.00 from $49.00 previously
Guggenheim downgraded Adagio Therapeutics from Buy to Neutral
Stifel downgraded Adagio Therapeutics from Buy to Hold and set a new price target of $9.00 from $50.00 previously
Morgan Stanley upgraded Adagio Therapeutics from Equal-Weight to Overweight and set a new price target of $49.00
Morgan Stanley initiated coverage of Adagio Therapeutics with a rating of Equal-Weight and set a new price target of $33.00
Jefferies initiated coverage of Adagio Therapeutics with a rating of Buy and set a new price target of $60.00
Stifel initiated coverage of Adagio Therapeutics with a rating of Buy and set a new price target of $57.00
WALTHAM, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Jeremy Gowler as chief operating and commercial officer, effective December 16, 2022, and the promotion of Pete Schmidt, M.D. to chief medical officer, effective immediately. In his new role Mr. Gowler will oversee operations and commercial activities for the company. Dr. Schmidt will be responsible for overseeing all medical, clinical development and regulatory activities at Invivyd. Dr. Ellie Hershberger, Invivyd's chief development officer, is departing f
WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Christine Lindenboom, senior vice president investor relations & corporate communications at Alnylam Pharmaceuticals, Inc., to its board of directors. In addition, Redonda Miller, M.D., M.B.A., president of The Johns Hopkins Hospital, has stepped down from her position on the board. "We are excited to welcome Christine to our board of directors where her business acumen and deep knowledge of the biopharmaceutical industry will round out and enhance our current b
WALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Invivyd, (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Fred Driscoll as interim CFO as well as headcount changes to align resources to its key programs. The changes are designed to improve capital efficiency by reallocating resources to programs and functions to support our key activities on an accelerated timeline. As part of the resource realignment, the company is building out additional discovery and early development positions and has eliminated several corporate and commercial positions, among others, to execute effi
WALTHAM, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ:ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that the company's Board of Directors has appointed David Hering interim chief executive officer, effective immediately. Mr. Hering, who will also remain the company's chief operating officer, succeeds Tillman Gerngross, Ph.D., who has resigned as CEO and director of Adagio. "We are highly confident in Dave's leadership and the entire Adagio leadership team," said René Russo, Pharm.D., co-founder and chai
Multiple Initiatives Undertaken for ADG20 Assessment, Including Analysis of Clinical Data at 300mg Dose and Exploring Higher Doses of ADG20 in the Clinic Company Pursuing Portfolio of Antibodies in Response to Continuously Emerging SARS-CoV-2 Variants WALTHAM, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (NASDAQ:ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today outlined strategic initiatives for its ADG20 program, as well as research efforts to address SARS-CoV-2 and other coronaviruses. ADG20 is an investigational monoclona
SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)
SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)
SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)
SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)
SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)
SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)
SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)
SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)
SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)
SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)